Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
FP10 - Palliative and Supportive Care
- Type: Posters (Featured)
- Track: Palliative and Supportive Care
- Presentations: 1
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
FP10.01 - The Efficacy of Immunotherapy in non-Small Cell Lung Cancer Patients with Uncommon Mutations: a Real World Research from Single Site
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
P14 - Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 7
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P14.01 - Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
00:00 - 00:00 | Presenter: Matthew D. Hellmann
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
MA02 - RET and Novel Combinations of Osimertinib
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 09:30 - 10:30, Program Auditorium
-
+
MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
09:30 - 09:35 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA02.06 - Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
10:05 - 10:10 | Presenter: Li Zhang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 5
- Moderators:Rina Hui
- Coordinates: 9/09/2021, 09:30 - 10:30, Program Auditorium
-
+
OA09.03 - Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
09:50 - 10:00 | Presenter: Shirish M. Gadgeel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- Type: Workshop
- Track: N.A.
- Presentations: 9
- Moderators:Caicun Zhou
- Coordinates: 9/11/2021, 22:15 - 23:45, Program Auditorium
-
+
WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
23:13 - 23:23 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 6
- Moderators:Helena A Yu
- Coordinates: 9/12/2021, 18:45 - 19:45, Program Auditorium
-
+
OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
18:55 - 19:05 | Presenter: Pasi A. Janne
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 9
- Coordinates: 9/13/2021, 17:30 - 18:30, Program Auditorium
-
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.